Evan S. Dellon, MD, MPH - Stepping Up the Management of Eosinophilic Esophagitis: Answering Key Questions on Diagnosis and Use of Pharmacotherapies

Please visit answersincme.com/XFS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in esophageal disease addresses common queries related to the diagnosis and management of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Identify diagnostic criteria and practical strategies to facilitate the timely diagnosis of EoE; Review the clinical impact of pharmacotherapies in patients with EoE; and Discuss personalized strategies to optimize patient outcomes with pharmacotherapies in EoE.

Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

Please visit answersincme.com/JTB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric epilepsy discusses strategies for optimizing the care of children and adults with Lennox-Gastaut syndrome (LGS). Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to accurately recognize LGS in children and adults; Evaluate the latest pharmacologic treatment strategies available for patients with LGS; and Outline approaches to optimize the long-term care of patients with LGS.

Please visit answersincme.com/WKB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses early-stage Alzheimer’s Disease (AD). Upon completion of this activity, participants should be better able to: Describe the multidisciplinary process of screening patients for early-stage AD; Describe the role primary care providers play in the multidisciplinary process of diagnosing patients with early-stage AD; and Outline strategies for counseling patients and caregivers about early intervention for early-stage AD.

Please visit answersincme.com/TDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metabolic diseases discusses metachromatic leukodystrophy (MLD). Upon completion of this activity, participants should be better able to: Explain the clinical burden and unmet needs in MLD; Describe the signs and symptoms of MLD to facilitate early diagnosis and intervention; and Outline potential strategies to optimize outcomes for patients with MLD.

Please visit answersincme.com/XCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in urology discuss the latest data for treatments of overactive bladder. Upon completion of this activity, participants should be better able to: Review the current treatment landscape of OAB; Discuss the clinical significance of the latest efficacy and safety data for beta-3 adrenergic agonists for the treatment of OAB; and Outline evidence-based, patient-centered strategies to optimally use beta-3 adrenergic agonists for the treatment of patients with OAB.

Please visit answersincme.com/KWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in bipolar disorder and a patient advocate discuss patient-centered care for people with bipolar I. Upon completion of this activity, participants should be better able to: Identify patient-centered strategies to optimize the timely diagnosis of bipolar I disorder (BD-I); Review goal-oriented therapeutic approaches that address the personalized needs of patients with BD-I; and Outline strategies to ensure the delivery of patient-centric care that incorporates patients’ wishes, values, priorities, and goals.

Please visit answersincme.com/WSK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Evan S. Dellon, MD, MPH, an expert in esophageal disease, discusses best practices to facilitate timely diagnosis of eosinophilic esophagitis (EoE) through symptom recognition and referral at the emergency department. Upon completion of this activity, participants should be better able to: Recognize the consequences of untreated eosinophilic esophagitis (EoE), including the burden of food impaction; Identify best practices to facilitate the timely diagnosis and management of EoE through symptom recognition and referral; and Review the available therapeutic modalities for EoE that support the need for timely referral. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.